{"nctId":"NCT00622284","briefTitle":"Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes","startDateStruct":{"date":"2008-02"},"conditions":["Diabetes Mellitus, Type 2"],"count":1560,"armGroups":[{"label":"BI 1356 5mg, once daily","type":"EXPERIMENTAL","interventionNames":["Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg","Drug: BI 1356"]},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo identical to BI 1356 5mg","Drug: Glimepiride"]}],"interventions":[{"name":"Placebo identical to BI 1356 5mg","otherNames":[]},{"name":"Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg","otherNames":[]},{"name":"BI 1356","otherNames":[]},{"name":"Glimepiride","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n1. Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug\n2. Glycosylated haemoglobin (HbA1c) 6.0 - 9.0% at screening for patients treated with metformin and one other oral antidiabetic drug\n3. HbA1c 6.5 - 10.0% at screening for patients treated with metformin alone\n4. HbA1c 6.5 - 10.0% at beginning of the placebo run-in phase\n\nExclusion criteria:\n\n1. Myocardial infarction, stroke or transient ischemic attack (TIA)\n2. Impaired hepatic function\n3. Renal failure or renal impairment\n4. Treatment with rosiglitazone or pioglitazone within 6 months prior to screening\n5. Treatment with insulin or glucagon-like peptide 1 (GLP-1) analogue/antagonists within 3 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 52","description":"This co-primary endpoint, change from baseline, reflects the Week 52 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.03"},{"groupId":"OG001","value":"-0.57","spread":"0.03"}]}]}]},{"type":"PRIMARY","title":"HbA1c Change From Baseline at Week 104","description":"This co-primary endpoint, change from baseline, reflects the Week 104 HbA1c percent minus the baseline HbA1c percent. Means are treatment adjusted for baseline HbA1c and the number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.16","spread":"0.03"},{"groupId":"OG001","value":"-0.36","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline at Week 52","description":"This key secondary endpoint, change from baseline, reflects the Week 52 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.12","spread":"0.13"},{"groupId":"OG001","value":"1.38","spread":"0.14"}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline at Week 104","description":"This key secondary endpoint, change from baseline, reflects the Week 104 body weight minus the baseline body weight. Means are treatment adjusted for baseline HbA1c, baseline weight and the number of previous antidiabetic-medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.16"},{"groupId":"OG001","value":"1.29","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycaemic Events up to 52 Weeks","description":"A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a home blood glucose monitoring (HBGM) of below 55 mg/dl (3.1 mmol/L)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"249","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Hypoglycaemic Events up to 104 Weeks","description":"A hypoglycaemic event is defined as patient showing clinical signs suggestive of low blood glucose confirmed by a HBGM of below 55 mg/dl (3.1 mmol/L)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"280","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline at Week 52","description":"This change from baseline reflects the Week 52 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and the number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.40","spread":"1.25"},{"groupId":"OG001","value":"-15.24","spread":"1.26"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose (FPG) Change From Baseline at Week 104","description":"This change from baseline reflects the Week 104 FPG minus the Baseline FPG. Means are treatment adjusted for baseline HbA1c, baseline FPG and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.34","spread":"1.46"},{"groupId":"OG001","value":"-8.72","spread":"1.47"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 52","description":"The percentage of patients with an HbA1c value below 7.0% at week 52, based upon patients with baseline HbA1c \\>= 7%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c \\>= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.6","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <7.0% at Week 104","description":"The percentage of patients with an HbA1c value below 7.0% at week 104, based upon patients with baseline HbA1c \\>= 7%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c \\>= 7.0%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.0","spread":null},{"groupId":"OG001","value":"28.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <6.5% at Week 52","description":"The percentage of patients with an HbA1c value below 6.5% at week 52, based upon patients with baseline HbA1c \\>= 6.5%. If a patient did not have an HbA1c value at week 52 they were considered a failure, so HbA1c \\>= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c <6.5% at Week 104","description":"The percentage of patients with an HbA1c value below 6.5% at week 104, based upon patients with baseline HbA1c \\>= 6.5%. If a patient did not have an HbA1c value at week 104 they were considered a failure, so HbA1c \\>= 6.5%. The logistic regression is treatment adjusted for baseline HbA1c and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","spread":null},{"groupId":"OG001","value":"14.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With HbA1c Lowering by 0.5% at Week 104","description":"Occurrence of relative efficacy response, defined as a lowering of 0.5% HbA1c at week 104","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2","spread":null},{"groupId":"OG001","value":"33.5","spread":null}]}]}]},{"type":"SECONDARY","title":"2 hr Postprandial Glucose (PPG) Change From Baseline at Week 104","description":"This change from baseline reflects the Week 104 2 hr PPG minus the Baseline 2hr PPG. Means are treatment adjusted for baseline HbA1c, baseline 2hr PPG and number of previous anti-diabetic medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.47","spread":"4.32"},{"groupId":"OG001","value":"-18.72","spread":"4.28"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 4","description":"Difference of base percent value \\[Week x(%) - baseline (%)\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.41"},{"groupId":"OG001","value":"-0.33","spread":"0.46"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 8","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.59"},{"groupId":"OG001","value":"-0.58","spread":"0.62"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 12","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.64"},{"groupId":"OG001","value":"-0.75","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 16","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.45","spread":"0.66"},{"groupId":"OG001","value":"-0.78","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 28","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.43","spread":"0.73"},{"groupId":"OG001","value":"-0.74","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 40","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.77"},{"groupId":"OG001","value":"-0.69","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 52","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.82"},{"groupId":"OG001","value":"-0.63","spread":"0.85"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 65","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.32","spread":"0.91"},{"groupId":"OG001","value":"-0.53","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 78","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.22","spread":"0.92"},{"groupId":"OG001","value":"-0.43","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 91","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.94"},{"groupId":"OG001","value":"-0.43","spread":"0.90"}]}]}]},{"type":"SECONDARY","title":"HbA1c Change at Week 104","description":"The Full Analysis Set (FAS) included all treated and randomized patients with a baseline and at least one on-treatment HbA1c measurement available during the first phase of the study. Last observation carried forward (LOCF) was used as imputation rule.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.21","spread":"0.95"},{"groupId":"OG001","value":"-0.41","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline Lipid Parameter Cholesterol at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"14"},{"groupId":"OG001","value":"1","spread":"14"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline Lipid Parameter HDL at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"9"},{"groupId":"OG001","value":"0","spread":"9"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline Lipid Parameter Low Density Lipoprotein (LDL) at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":"23"},{"groupId":"OG001","value":"3","spread":"25"}]}]}]},{"type":"SECONDARY","title":"Change in Baseline Lipid Parameter Triglyceride at Week 104","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11","spread":"153"},{"groupId":"OG001","value":"-7","spread":"148"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":135,"n":776},"commonTop":["Hypoglycaemia","Nasopharyngitis","Back pain","Upper respiratory tract infection","Diarrhoea"]}}}